KCNJ2 (P63252) variants and mutations
KCNJ2 (also known as P63252) is a human protein-coding gene encoding an inward rectifier potassium channel 2 protein. Its inward-rectifier current stabilizes the resting membrane potential in cardiac and skeletal muscle and contributes to terminal cardiac repolarization. Loss-of-function variants cause Andersen-Tawil syndrome, while gain-of-function variants can cause short-QT syndrome. This analysis covers 969 KCNJ2 variants and mutations. Of these, 85% have computational variant effect predictions. Disease context includes Andersen-Tawil syndrome, Cardiodysrhythmic potassium-sensitive periodic paralysis, and short QT syndrome type 3. Example KCNJ2 variants include M1T, G2D, and G2R.
Variant analysis overview
- Gene: KCNJ2
- Protein: P63252
- UniProt accession: P63252
- Organism: Homo sapiens
- Variants analyzed: 969
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 628 unspecified-consequence records; 196 synonymous variants; 126 missense variants; 6 frameshift variants; 2 in-frame deletions; 4 stop-gained variants; 1 stop lost; 6 substitution
- Prediction scores: 827 variants have prediction scores (85% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Andersen-Tawil syndrome, Cardiodysrhythmic potassium-sensitive periodic paralysis, short QT syndrome type 3, Familial short QT syndrome, atrial fibrillation, familial, 9, atrial fibrillation, Abnormality of the cardiovascular system, cardiac arrhythmia, periodic paralysis, Varicose veins, odontogenesis, atrial flutter.
Protein structure and variant hotspots
- Protein features: 2 transmembrane segments; 1 binding sites; 1 post-translational modification sites.
- Structural context: 107 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable KCNJ2 variants
Examples include M1T, G2D, G2R, G2G, S3T, S3S, S3R, V4E. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs786205810, ClinGen CA302009, ClinVar RCV000170969, ClinVar RCV002433737, MetaLR 0.23, MetaSVM -0.69, Uncertain significance, Cardiovascular phenotype; not provided
- G2D (p.Gly2Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G2R (p.Gly2Arg), rs2509920681, ClinGen CA400859469, ClinVar RCV003781719, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- G2G (p.Gly2Gly), rs1452371663, gnomAD 17-70175045-C-T, CADD 11.50
- S3T (p.Ser3Thr), rs2509920685, ClinGen CA400859478, ClinVar RCV003324404, Uncertain significance, not specified
- S3S (p.Ser3Ser), rs1598210962, gnomAD 17-70175048-T-C, CADD 7.82
- S3R (p.Ser3Arg), gnomAD 17-70175048-T-G, REVEL 0.26, MetaLR 0.08
- V4E (p.Val4Glu), Ensembl rs2074384009, MetaLR 0.08, MetaSVM -1.09
- V4M (p.Val4Met), ExAC rs756248184, gnomAD rs756248184, REVEL 0.19, MetaLR 0.13
- R5* (p.Arg5Ter), rs1042485, ClinGen CA400859487, NCI-TCGA Cosmic COSV9969, cosmic curated COSV99696, AlphaMissense 0.26, MetaLR 0.37, Pathogenic
- R5G (p.Arg5Gly), rs1042485, ClinGen CA293702895, ClinVar RCV002512440, gnomAD rs1042485, AlphaMissense 0.26, MetaLR 0.37, Uncertain significance, Short QT syndrome type 3; Andersen Tawil syndrome
- R5L (p.Arg5Leu), cosmic curated COSV54663, REVEL 0.48, MetaLR 0.36
- R5Q (p.Arg5Gln), rs764311511, ClinGen CA8738678, ClinVar RCV001361201, ExAC rs764311511, REVEL 0.27, MetaLR 0.26, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- R5R (p.Arg5Arg), rs1042485, gnomAD 17-70175052-C-A, AlphaMissense 0.26, MetaLR 0.37
- T6I (p.Thr6Ile), rs754091630, ClinGen CA8738679, ClinVar RCV002269600, ExAC rs754091630, REVEL 0.11, MetaLR 0.05, Uncertain significance, not provided
- T6P (p.Thr6Pro), Ensembl rs1598210971, MetaLR 0.05, MetaSVM -1.06
- T6S (p.Thr6Ser), rs1598210971, ClinGen CA400859492, ClinVar RCV004520982, REVEL 0.04, MetaLR 0.06, Likely benign, Cardiovascular phenotype
- T6A (p.Thr6Ala), gnomAD 17-70175055-A-G, REVEL 0.08, MetaLR 0.04
- T6T (p.Thr6Thr), rs2144376313, gnomAD 17-70175057-C-A, CADD 9.25
- N7K (p.Asn7Lys), rs2074384101, ClinGen CA400859502, ClinVar RCV003278158, Uncertain significance, Cardiovascular phenotype
- R8C (p.Arg8Cys), rs529080615, ClinGen CA8738680, NCI-TCGA Cosmic COSV9969, cosmic curated COSV99696, REVEL 0.28, MetaLR 0.26, Uncertain significance, Cardiovascular phenotype; not specified; Atrial fibrillation, familial, 9
- R8H (p.Arg8His), rs140090605, ClinGen CA8738681, ClinVar RCV001047780, ClinVar RCV005394677, REVEL 0.14, MetaLR 0.10, Conflicting interpretations, Andersen Tawil syndrome; Short QT syndrome type 3; Atrial fibrillation, familial
- R8L (p.Arg8Leu), ESP rs140090605, ExAC rs140090605, TOPMed rs140090605, gnomAD rs140090605, REVEL 0.21, MetaLR 0.22, Uncertain significance, Cardiovascular phenotype
- R8S (p.Arg8Ser), gnomAD 17-70175061-C-A, REVEL 0.16, MetaLR 0.21
- R8R (p.Arg8Arg), gnomAD 17-70175063-C-A, CADD 11.00
- Y9Y (p.Tyr9Tyr), gnomAD 17-70175066-C-T, CADD 4.28
- S10G (p.Ser10Gly), TOPMed rs1252050049, gnomAD rs1252050049, REVEL 0.27, MetaLR 0.28
- S10N (p.Ser10Asn), TOPMed rs1187051577, gnomAD rs1187051577, REVEL 0.25, MetaLR 0.20, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- S10T (p.Ser10Thr), cosmic curated COSV10806, MetaLR 0.31, MetaSVM -0.62
- I11V (p.Ile11Val), rs879760912, ClinGen CA293702896, ClinVar RCV002937642, Ensembl rs879760912, AlphaMissense 0.06, MetaLR 0.10, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- I11I (p.Ile11Ile), rs1463813330, gnomAD 17-70175072-C-T, CADD 0.41
- V12I (p.Val12Ile), NCI-TCGA Cosmic COSV5465, cosmic curated COSV54659, gnomAD rs2074384248, REVEL 0.22, MetaLR 0.22, Variant assessed as somatic; moderate impact.
- V12A (p.Val12Ala), gnomAD 17-70175074-T-C, REVEL 0.30, MetaLR 0.24
- V12V (p.Val12Val), rs1169880303, gnomAD 17-70175075-C-G, CADD 5.05
- S13Y (p.Ser13Tyr), cosmic curated COSV99696
- S13S (p.Ser13Ser), rs1292592429, gnomAD 17-70175078-T-C, CADD 11.20
- S14L (p.Ser14Leu), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54661, REVEL 0.18, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- S14S (p.Ser14Ser), rs2144376348, gnomAD 17-70175081-A-G, CADD 1.26
- E15D (p.Glu15Asp), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54663, MetaLR 0.13, MetaSVM -1.03, Variant assessed as somatic; moderate impact.
- E16D (p.Glu16Asp), TOPMed rs1470684052, gnomAD rs1470684052, REVEL 0.17, MetaLR 0.18, Likely benign
- E16G (p.Glu16Gly), ExAC rs758776917, TOPMed rs758776917, gnomAD rs758776917, REVEL 0.39, MetaLR 0.32
- E16K (p.Glu16Lys), cosmic curated COSV54660, MetaLR 0.32, MetaSVM -0.59
- E16Q (p.Glu16Gln), rs1203915572, ClinGen CA400859737, ClinVar RCV002335308, ClinVar RCV005213682, REVEL 0.24, MetaLR 0.35, Uncertain significance, Cardiovascular phenotype; Short QT syndrome type 3; Andersen Tawil syndrome
- E16E (p.Glu16Glu), rs1470684052, gnomAD 17-70175087-A-G, CADD 8.63
- D17G (p.Asp17Gly), ExAC rs780600986, gnomAD rs780600986, REVEL 0.23, MetaLR 0.06, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- D17H (p.Asp17His), gnomAD rs1331601602, REVEL 0.25, AlphaMissense 0.14, Uncertain significance
- D17N (p.Asp17Asn), rs1331601602, ClinGen CA400859744, ClinVar RCV000656202, gnomAD rs1331601602, AlphaMissense 0.14, MetaLR 0.13, Uncertain significance, Wolff-Parkinson-White pattern
- D17D (p.Asp17Asp), rs141965142, gnomAD 17-70175090-C-T, CADD 8.37
- G18C (p.Gly18Cys), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54661, REVEL 0.57, MetaLR 0.48, Variant assessed as somatic; moderate impact.
- G18R (p.Gly18Arg), rs947488726, ClinGen CA400859751, ClinVar RCV003798000, AlphaMissense 0.08, MetaLR 0.33, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- G18S (p.Gly18Ser), rs947488726, ClinGen CA293702897, NCI-TCGA Cosmic COSV5466, REVEL 0.48, AlphaMissense 0.08, Uncertain significance, Cardiovascular phenotype; Andersen Tawil syndrome; Short QT syndrome type 3
- G18G (p.Gly18Gly), gnomAD 17-70175093-T-C, CADD 9.44
- M19I (p.Met19Ile), cosmic curated COSV10503, NCI-TCGA TCGA novel, REVEL 0.24, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- M19V (p.Met19Val), gnomAD 17-70175094-A-G, REVEL 0.19, MetaLR 0.07
- K20K (p.Lys20Lys), rs768120590, gnomAD 17-70175099-G-A, CADD 7.59
- L21F (p.Leu21Phe), Ensembl rs2144376380
- A22T (p.Ala22Thr), gnomAD 17-70175103-G-A, REVEL 0.12, MetaLR 0.06
- T23P (p.Thr23Pro), cosmic curated COSV54661, MetaLR 0.14, MetaSVM -0.98
- T23T (p.Thr23Thr), gnomAD 17-70175108-C-T, CADD 7.35
- M24T (p.Met24Thr), TOPMed rs1332633060, MetaLR 0.11, MetaSVM -1.04
- M24V (p.Met24Val), rs1441314140, ClinGen CA400859793, ClinVar RCV003065573, TOPMed rs1441314140, REVEL 0.06, MetaLR 0.07, Uncertain significance, Cardiovascular phenotype; Andersen Tawil syndrome; Short QT syndrome type 3
- M24K (p.Met24Lys), gnomAD 17-70175110-T-A, REVEL 0.11, MetaLR 0.10
- A25P (p.Ala25Pro), TOPMed rs1316063007, gnomAD rs1316063007, REVEL 0.13, MetaLR 0.05
- A25T (p.Ala25Thr), cosmic curated COSV54662, MetaLR 0.10, MetaSVM -1.09
- A25V (p.Ala25Val), gnomAD 17-70175113-C-T, REVEL 0.14, MetaLR 0.11
- A25A (p.Ala25Ala), rs1217136489, gnomAD 17-70175114-A-G, CADD 2.99
- V26A (p.Val26Ala), cosmic curated COSV54664
- V26I (p.Val26Ile), Ensembl rs1567822841, MetaLR 0.06, MetaSVM -1.06
- V26F (p.Val26Phe), gnomAD 17-70175115-G-T, REVEL 0.23, MetaLR 0.10
- V26V (p.Val26Val), rs750956717, gnomAD 17-70175117-T-G, CADD 0.35
- A27S (p.Ala27Ser), NCI-TCGA TCGA novel, MetaLR 0.09, MetaSVM -1.07, Variant assessed as somatic; moderate impact.
- A27A (p.Ala27Ala), rs2074384649, gnomAD 17-70175120-A-C, CADD 2.76
- N28H (p.Asn28His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N28S (p.Asn28Ser), rs2074384666, ClinGen CA400859823, NCI-TCGA Cosmic COSV9969, cosmic curated COSV99696, AlphaMissense 0.07, MetaLR 0.16, Uncertain significance, Brugada syndrome
- G29D (p.Gly29Asp), cosmic curated COSV54661, MetaLR 0.27, MetaSVM -0.73
- G29V (p.Gly29Val), gnomAD 17-70175125-G-T, REVEL 0.47, MetaLR 0.28
- G29A (p.Gly29Ala), gnomAD 17-70175125-G-C, REVEL 0.29, MetaLR 0.20
- G29G (p.Gly29Gly), rs1027878057, gnomAD 17-70175126-C-T, CADD 9.76
- F30S (p.Phe30Ser), rs2509920752, ClinGen CA400859837, ClinVar RCV003796020, REVEL 0.18, MetaLR 0.15, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- F30V (p.Phe30Val), cosmic curated COSV10879, MetaLR 0.12, MetaSVM -1.02
- F30Y (p.Phe30Tyr), gnomAD 17-70175128-T-A, REVEL 0.07, MetaLR 0.05
- F30L (p.Phe30Leu), gnomAD 17-70175129-T-G, REVEL 0.16, MetaLR 0.09
- G31R (p.Gly31Arg), cosmic curated COSV54660
- G31V (p.Gly31Val), cosmic curated COSV54660, Ensembl rs2144376399, MetaLR 0.33, MetaSVM -0.63
- G31E (p.Gly31Glu), gnomAD 17-70175131-G-A, REVEL 0.51, MetaLR 0.45
- G31G (p.Gly31Gly), rs1202288240, gnomAD 17-70175132-G-A, CADD 10.00
- N32K (p.Asn32Lys), rs67120636, ClinGen CA400859854, ClinVar RCV003784904, REVEL 0.28, MetaLR 0.13, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- N32S (p.Asn32Ser), gnomAD 17-70175134-A-G, REVEL 0.14, MetaLR 0.11
- N32N (p.Asn32Asn), rs67120636, gnomAD 17-70175135-C-T, CADD 1.00
- G33R (p.Gly33Arg), rs375727662, ClinGen CA400859855, cosmic curated COSV10503, ClinVar RCV001508992, REVEL 0.38, MetaLR 0.32, Uncertain significance, Long QT syndrome; Andersen Tawil syndrome; Short QT syndrome type 3
- G33G (p.Gly33Gly), rs769513425, gnomAD 17-70175138-G-A, CADD 1.73
- K34E (p.Lys34Glu), NCI-TCGA TCGA novel, MetaLR 0.61, MetaSVM 0.13, Variant assessed as somatic; moderate impact.
- K34N (p.Lys34Asn), rs1476737505, ClinGen CA400859865, ClinVar RCV002036431, ClinVar RCV003161305, REVEL 0.26, MetaLR 0.55, Conflicting interpretations, Cardiovascular phenotype; not provided; Short QT syndrome type 3
- K34R (p.Lys34Arg), rs772815957, ClinGen CA8738690, ClinVar RCV000818687, ExAC rs772815957, REVEL 0.46, MetaLR 0.57, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- K34T (p.Lys34Thr), gnomAD 17-70175140-A-C, REVEL 0.54, MetaLR 0.61
- S35G (p.Ser35Gly), gnomAD rs1192608882, REVEL 0.25, MetaLR 0.39
- S35R (p.Ser35Arg), NCI-TCGA TCGA novel, MetaLR 0.40, MetaSVM -0.48, Variant assessed as somatic; moderate impact.
- S35T (p.Ser35Thr), ExAC rs762818989, gnomAD rs762818989, REVEL 0.33, MetaLR 0.44
- S35S (p.Ser35Ser), rs1470900088, gnomAD 17-70175144-T-C, CADD 8.87
- K36E (p.Lys36Glu), rs2509920772, ClinGen CA400859876, ClinVar RCV003039560, REVEL 0.29, MetaLR 0.15, Uncertain significance, Short QT syndrome type 3; Andersen Tawil syndrome
- K36T (p.Lys36Thr), gnomAD 17-70175146-A-C, REVEL 0.20, MetaLR 0.11
- V37I (p.Val37Ile), rs2509920779, ClinGen CA400859884, ClinVar RCV004520981, Uncertain significance, Cardiovascular phenotype
- V37S (p.Val37Ser), gnomAD 17-70175147-AG-A, CADD 29.40
- V37V (p.Val37Val), gnomAD 17-70175150-C-T, CADD 6.64
- H38Y (p.His38Tyr), TOPMed rs2074384858, gnomAD rs2074384858, REVEL 0.34, MetaLR 0.37
- H38H (p.His38His), gnomAD 17-70175153-C-T, CADD 8.21
- T39I (p.Thr39Ile), gnomAD rs1367740803, REVEL 0.18, MetaLR 0.27, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- T39P (p.Thr39Pro), Ensembl rs1598211032, MetaLR 0.17, MetaSVM -0.92
- T39A (p.Thr39Ala), gnomAD 17-70175154-A-G, REVEL 0.14, MetaLR 0.15
- R40* (p.Arg40Ter), rs786205811, ClinGen CA302012, cosmic curated COSV99078, ClinVar RCV000170970, Pathogenic
- R40L (p.Arg40Leu), rs766143485, ClinGen CA400859903, ClinVar RCV003019194, REVEL 0.27, AlphaMissense 0.20, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- R40P (p.Arg40Pro), rs766143485, ClinGen CA16615669, ClinVar RCV000473222, ExAC rs766143485, AlphaMissense 0.20, MetaLR 0.23, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- R40Q (p.Arg40Gln), rs766143485, ClinGen CA8738692, ClinVar RCV000308982, ClinVar RCV000347359, REVEL 0.20, AlphaMissense 0.20, Conflicting interpretations, Cardiovascular phenotype; not provided; Andersen Tawil syndrome
- R40R (p.Arg40Arg), rs786205811, gnomAD 17-70175157-C-A, CADD 10.10
- Q41* (p.Gln41Ter), cosmic curated COSV54663
- Q41P (p.Gln41Pro), cosmic curated COSV10584, MetaLR 0.07, MetaSVM -1.05
- Q41R (p.Gln41Arg), Ensembl rs2074384966, REVEL 0.10, MetaLR 0.03
- Q41K (p.Gln41Lys), gnomAD 17-70175160-C-A, REVEL 0.12, MetaLR 0.06
- Q42S (p.Gln42Ser), cosmic curated COSV10638, MetaLR 0.04, MetaSVM -1.06
- Q42del (p.Gln42del), rs1567822866, gnomAD 17-70175158-GACA-, CADD 17.90
- C43F (p.Cys43Phe), ExAC rs774424161, TOPMed rs774424161, gnomAD rs774424161, MetaLR 0.08, MetaSVM -1.08, Benign
- C43R (p.Cys43Arg), cosmic curated COSV54660, gnomAD rs1170369013, REVEL 0.14, MetaLR 0.06
- C43Y (p.Cys43Tyr), rs774424161, ClinGen CA8738693, cosmic curated COSV54664, ClinVar RCV001362741, REVEL 0.13, MetaLR 0.07, Conflicting interpretations, Cardiovascular phenotype; Andersen Tawil syndrome; Short QT syndrome type 3
- R44K (p.Arg44Lys), rs2144376473, ClinGen CA400859928, ClinVar RCV001925374, Ensembl rs2144376473, AlphaMissense 0.09, MetaLR 0.09, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- R44R (p.Arg44Arg), rs551369705, gnomAD 17-70175171-G-A, CADD 9.97
- S45C (p.Ser45Cys), gnomAD 17-70175172-A-T, REVEL 0.30, MetaLR 0.10
- S45R (p.Ser45Arg), gnomAD 17-70175174-C-A, REVEL 0.17, MetaLR 0.11
- S45S (p.Ser45Ser), rs1319908340, gnomAD 17-70175174-C-T, CADD 10.00
- R46C (p.Arg46Cys), rs2074385043, ClinGen CA400859943, NCI-TCGA Cosmic COSV5466, cosmic curated COSV54661, REVEL 0.59, AlphaMissense 0.98, Uncertain significance, Short QT syndrome type 3; Andersen Tawil syndrome
- R46G (p.Arg46Gly), rs2074385043, ClinGen CA400859942, ClinVar RCV001877968, TOPMed rs2074385043, AlphaMissense 0.98, MetaLR 0.41, Uncertain significance, Short QT syndrome type 3; Andersen Tawil syndrome
- R46H (p.Arg46His), rs1271319212, ClinGen CA400859944, ClinVar RCV003149379, ClinVar RCV005215990, REVEL 0.65, MetaLR 0.41, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3; not provided
- R46S (p.Arg46Ser), NCI-TCGA Cosmic COSV5466, TOPMed rs2074385043, MetaLR 0.41, MetaSVM -0.35, Uncertain significance
- R46P (p.Arg46Pro), gnomAD 17-70175176-G-C, REVEL 0.69, MetaLR 0.41
- R46R (p.Arg46Arg), rs997406384, gnomAD 17-70175177-C-T, CADD 10.10
- V48M (p.Val48Met), rs2509920826, ClinGen CA400859955, ClinVar RCV003805796, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- K49R (p.Lys49Arg), gnomAD 17-70175185-A-G, REVEL 0.42, MetaLR 0.71
- K49K (p.Lys49Lys), rs566444796, gnomAD 17-70175186-G-A, CADD 10.30
- K50R (p.Lys50Arg), rs2144376499, ClinGen CA400859973, ClinVar RCV001928935, ClinVar RCV002484575, AlphaMissense 0.45, MetaLR 0.95, Uncertain significance, Atrial fibrillation, familial, 9; Short QT syndrome type 3; Andersen Tawil syndr
- K50Q (p.Lys50Gln), gnomAD 17-70175187-A-C, REVEL 0.95, MetaLR 0.96
- K50K (p.Lys50Lys), gnomAD 17-70175189-A-G, CADD 8.37
- D51G (p.Asp51Gly), Ensembl rs2074385111
- D51H (p.Asp51His), cosmic curated COSV54660
- D51D (p.Asp51Asp), gnomAD 17-70175192-T-C, CADD 1.89
- G52D (p.Gly52Asp), NCI-TCGA Cosmic COSV9969, Variant assessed as somatic; moderate impact.
- G52V (p.Gly52Val), rs1555603894, ClinGen CA400859990, NCI-TCGA Cosmic COSV9969, cosmic curated COSV99696, AlphaMissense 1.00, MetaLR 0.97, Likely pathogenic, Cardiovascular phenotype
- H53R (p.His53Arg), rs1598211051, ClinGen CA400859995, ClinVar RCV000793841, ClinVar RCV006342555, AlphaMissense 0.10, MetaLR 0.57, Uncertain significance, Cardiovascular phenotype; Andersen Tawil syndrome; Short QT syndrome type 3
- C54F (p.Cys54Phe), rs199473650, ClinGen CA145011, ClinVar RCV000023027, ClinVar RCV000058293, AlphaMissense 0.97, MetaLR 0.95, Likely pathogenic, Andersen Tawil syndrome
- C54G (p.Cys54Gly), rs2144376507, ClinGen CA400860001, ClinVar RCV002042343, Ensembl rs2144376507, AlphaMissense 0.93, MetaLR 0.92, Uncertain significance, Short QT syndrome type 3; Andersen Tawil syndrome
- N55I (p.Asn55Ile), gnomAD rs1277940062, REVEL 0.88, MetaLR 0.95
- N55N (p.Asn55Asn), rs534260324, gnomAD 17-70175204-T-C, CADD 1.33
- V56A (p.Val56Ala), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54660, TOPMed rs2074385241, MetaLR 0.94, MetaSVM 1.09, Variant assessed as somatic; moderate impact.
- V56I (p.Val56Ile), rs1264595509, ClinGen CA400860014, ClinVar RCV001772578, TOPMed rs1264595509, REVEL 0.42, MetaLR 0.76, Uncertain significance, not provided
- V56V (p.Val56Val), rs370111593, gnomAD 17-70175207-T-C, CADD 0.73
- Q57* (p.Gln57Ter), rs2509920857, ClinGen CA400860022, ClinVar RCV003443514, Uncertain significance
- Q57H (p.Gln57His), rs2074385303, gnomAD rs2074385303, ClinGen CA400860027, ClinVar RCV002399049, REVEL 0.34, MetaLR 0.62, Uncertain significance, Cardiovascular phenotype
- Q57R (p.Gln57Arg), TOPMed rs1273518954, gnomAD rs1273518954, REVEL 0.44, MetaLR 0.60
- F58I (p.Phe58Ile), Ensembl rs2074385317, REVEL 0.90, MetaLR 0.87, Uncertain significance, Cardiovascular phenotype
- F58L (p.Phe58Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F58F (p.Phe58Phe), rs587781006, gnomAD 17-70175213-C-T, CADD 11.30
- I59S (p.Ile59Ser), Ensembl rs969836811
- N60D (p.Asn60Asp), cosmic curated COSV99696, MetaLR 0.92, MetaSVM 1.03
- N60S (p.Asn60Ser), rs1484750176, ClinGen CA400860046, ClinVar RCV001914205, ClinVar RCV002223328, REVEL 0.74, MetaLR 0.90, Uncertain significance, not provided; Short QT syndrome type 3; Andersen Tawil syndrome
- N60H (p.Asn60His), gnomAD 17-70175217-A-C, REVEL 0.76, MetaLR 0.80
- N60I (p.Asn60Ile), gnomAD 17-70175218-A-T, REVEL 0.94, MetaLR 0.94
- N60N (p.Asn60Asn), gnomAD 17-70175219-T-C, CADD 5.29
- V61L (p.Val61Leu), gnomAD 17-70175220-G-T, REVEL 0.49, MetaLR 0.65
- G62G (p.Gly62Gly), rs2144376552, gnomAD 17-70175225-T-C, CADD 1.02
- E63* (p.Glu63Ter), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54661, Variant assessed as somatic; high impact.
- E63G (p.Glu63Gly), NCI-TCGA Cosmic COSV5466, cosmic curated COSV54661, Variant assessed as somatic; moderate impact.
- E63K (p.Glu63Lys), Ensembl rs2144376556
- E63E (p.Glu63Glu), gnomAD 17-70175228-G-A, CADD 8.52
- K64R (p.Lys64Arg), rs2144376559, ClinGen CA400860074, ClinVar RCV001976353, Ensembl rs2144376559, AlphaMissense 0.09, MetaLR 0.68, Uncertain significance, Andersen Tawil syndrome; Short QT syndrome type 3
- K64K (p.Lys64Lys), rs2074385390, gnomAD 17-70175231-G-A, CADD 7.91
- G65V (p.Gly65Val), Ensembl rs2144376564
- R67Q (p.Arg67Gln), rs199473368, ClinGen CA302017, NCI-TCGA Cosmic COSV5466, cosmic curated COSV54662, AlphaMissense 0.36, MetaLR 0.95, Pathogenic/Likely pathogenic, not provided; Andersen Tawil syndrome; Short QT syndrome type 3
- R67W (p.Arg67Trp), rs104894580, ClinGen CA302015, cosmic curated COSV54660, ClinVar RCV000009478, REVEL 0.94, MetaLR 0.95, Pathogenic, in LQT7
- R67R (p.Arg67Arg), rs104894580, gnomAD 17-70175238-C-A, CADD 10.40
- Y68* (p.Tyr68Ter), cosmic curated COSV54664
- Y68C (p.Tyr68Cys), rs2144376588, ClinGen CA400860098, cosmic curated COSV54661, ClinVar RCV002251102, AlphaMissense 0.94, MetaLR 0.96, Uncertain significance, Andersen Tawil syndrome
- Y68D (p.Tyr68Asp), rs199473651, ClinGen CA329639, ClinVar RCV000058296, Ensembl rs199473651, AlphaMissense 0.98, MetaLR 0.96, not provided, Congenital long QT syndrome
Public KCNJ2 analysis runs
- KCNJ2 analysis run — KCNJ2 (969 variants) — completed 2026-08-18